The central obstacle in solid tumor CAR T therapy has always been target selection. The therapy works by collecting a patient’s own T cells, genetically engineering them to recognize a specific protein on the surface of cancer cells, and reinfusing them so they hunt down and destroy anything bearing that molecular signature. In blood cancers, this is relatively straightforward because malignant B cells display molecules such as CD19 that are dispensable elsewhere in the body. Solid tumors are different. Most of their defining abnormalities hide inside the cell, driven by mutated or fused genes operating in the nucleus, while the proteins displayed on the cell surface tend to be shared with healthy tissues. Attacking them risks catastrophic off-tumor toxicity, and tumors that do express a target often do so unevenly, allowing antigen-negative cells to survive and seed relapse.

The research team approached this problem from a different angle: instead of searching for surface proteins common to broad cancer types, they looked for surface proteins that are directly commanded into existence by the specific gene fusions that drive certain rare cancers. Alveolar soft-part sarcoma, or ASPS, is a striking example. This aggressive sarcoma, which disproportionately strikes adolescents and young adults, is caused by a chromosome rearrangement that fuses the TFE3 transcription factor gene to the ASPSCR1 gene. Translocation renal cell carcinoma, similarly, arises from fusions involving MiT/TFE-family transcription factors such as TFE3 or TFEB. Because these fusion proteins are aberrant transcription factors, they rewire the cell’s gene expression program wholesale, and the investigators reasoned that this rewiring might force cancer cells to display unique combinations of surface molecules.

Using gene expression profiling across primary and relapsed tumor samples, the team identified glycoprotein NMB, or GPNMB, as a molecule that fits the bill. GPNMB is a transmembrane glycoprotein that in these fusion-driven cancers is expressed at high levels, with striking uniformity across tumor cells and remarkable stability over time. In ASPS and translocation renal cell carcinoma samples, including tumors that had relapsed after prior therapies, essentially every malignant cell carried GPNMB on its surface. This homogeneity is exactly what a CAR T target needs, because it denies tumor cells the escape route of simply switching the target off. Equally important, GPNMB expression in normal tissues is low and restricted, raising the prospect of a workable therapeutic window.

With the target validated, the researchers engineered a CAR T cell product they named GCAR1. The construct couples an antibody-derived recognition domain that binds GPNMB to intracellular signaling modules that activate the T cell upon contact, triggering killing of the target cell and proliferation of the engineered population. In the laboratory, GCAR1 cells showed potent, selective cytotoxicity against patient-derived tumor cells, lysing GPNMB-positive cancer cells while sparing matched normal cells that lacked the protein. The activity extended beyond flat cultures of cells into three-dimensional patient-derived organoids, which better recapitulate the architecture and drug resistance of real tumors, and into xenograft models in which human tumors were implanted in immunodeficient mice. In those animal models, GCAR1 infusions produced marked tumor control, establishing preclinical proof that the approach could work in living tissue.

The pivotal step came with the launch of a first-in-human, open-label, individual-participant clinical trial, registered as NCT07104682, designed to test GCAR1 in patients with relapsed or refractory fusion-driven solid tumors. The study reported here includes an interim analysis of a participant with metastatic ASPS whose disease had progressed despite standard treatment. Following lymphodepleting chemotherapy to clear space for the engineered cells, the patient received a single infusion of GCAR1. The clinical response, while not a complete remission, was notable: imaging showed stable disease sustained for up to three months, and, strikingly, many of the patient’s non-target lesions, smaller metastatic deposits not formally measured as primary endpoints, resolved entirely on follow-up scans. In a cancer as relentless as ASPS, with few effective systemic options and a median survival historically measured in a few years from diagnosis, even disease stabilization with lesion regression represents a meaningful clinical signal.

Just as important as the efficacy signal was the safety profile. GCAR1 was well tolerated, without the severe cytokine release syndrome, neurotoxicity, or on-target off-tumor organ damage that has plagued some solid tumor CAR programs. The engineered cells were detectable in the patient’s peripheral blood for about a month after infusion, expanding as a polyclonal population, meaning that multiple distinct T cell clones carrying the receptor expanded in parallel rather than a single clone dominating. Polyclonal persistence is generally viewed favorably, as it suggests a robust, diverse immune response less vulnerable to outgrowth of tumor variants that could evade any single clone. The one-month persistence window is also consistent with a controlled, self-limited therapy, which may explain the clean toxicity profile even against a target like GPNMB that has low-level normal tissue expression.

The study did not stop at the celebration of a response, however. One lesion in the patient proved treatment-resistant, and the team subjected it to an advanced molecular interrogation known as spatial transcriptomics, a technique that maps which genes are active at precise locations within intact tissue. The analysis revealed that the resistant lesion harbored immunosuppressive niches, microanatomical pockets enriched for pathways and cell types that suppress T cell function, effectively creating local sanctuaries where the CAR T cells could not operate even when they reached the tumor. This finding transforms an apparent failure into a roadmap: resistance, in this case, was not about loss of the GPNMB target but about the tumor microenvironment building walls around the attacking cells.

That mechanistic insight pointed directly at a rational combination strategy. Immune checkpoint blockade, the class of drugs that includes antibodies against molecules such as PD-1 and its ligand PD-L1, works by releasing molecular brakes that tumors place on T cells. The researchers tested whether combining checkpoint blockade with GCAR1 would overcome the immunosuppressive niches, and in a xenograft model the combination produced synergy, with the two modalities together controlling tumors more effectively than either alone. For a translational program, this is a crucial result, because checkpoint inhibitors are already approved, widely available, and clinically familiar. A future trial testing GCAR1 alongside checkpoint blockade is an obvious and achievable next step, and the preclinical synergy data provide the justification.

The broader conceptual contribution of the study may ultimately matter more than any single clinical result. The MiT/TFE-family fusion proteins that drive ASPS and translocation renal cell carcinoma are master regulators, and the demonstration that their activity can be exploited through a surface readout like GPNMB establishes a general paradigm: oncogenic gene fusions, though intracellular and classically considered undruggable, can be converted into actionable surface targets by mapping the transcriptional programs they impose. The same strategy could in principle be extended to other fusion-driven cancers, a category that includes many pediatric sarcomas, leukemias, and carcinomas for which targeted drugs remain elusive. Rather than trying to inhibit an undruggable fusion protein directly, clinicians could train a patient’s immune system to recognize the distinctive surface signature that the fusion creates.

Challenges remain before GCAR1 or its successors become standard care. The clinical experience so far involves a single participant in an interim analysis, and larger cohorts will be needed to confirm response rates, define the optimal dosing, and fully characterize toxicities. The three-month duration of disease control, while encouraging, will need to extend into durable remissions, likely through combinations with checkpoint inhibitors or other microenvironment-modulating agents suggested by the spatial transcriptomics findings. Questions about whether resistance can emerge through GPNMB loss in other patients, and whether GPNMB expression levels in normal tissues vary enough between individuals to cause occasional toxicity, will require larger datasets. Nevertheless, the trajectory from target discovery through organoid and xenograft validation to a controlled, tolerated, clinically active infusion in a patient with one of oncology’s most feared sarcomas has been completed in a single study, a bench-to-bedside arc that few experimental therapies achieve so cleanly. For patients with ASPS, translocation renal cell carcinoma, and other fusion-driven solid tumors, the message is that the wall separating CAR T success in blood cancers from success in solid tumors is no longer impenetrable, and the first engineered cells are already through it.

The origin of CAR-T therapy lies in genetically reprogramming a patient’s own T cells to seek and destroy malignant or virally infected cells. This is achieved by extracting T cells, engineering them with CAR constructs that precisely target specific antigens, and reinfusing these altered cells back into the patient’s system. Despite its initial clinical successes—marked by rapid remission in many blood cancer patients—the longevity of CAR-T effects has been a consistent challenge. Cells gradually lose their cytotoxic vigour, and approximately half of recipients face cancer relapse, highlighting the need for a durable cell product that supports long-term immune surveillance.

Equally compelling is the intervention’s application against HIV, a virus notorious for hiding in latent reservoirs within immune cells. Current antiretroviral therapies (ART) suppress active viral replication but do not purge these reservoirs, necessitating lifelong medication with associated systemic toxicities. CAR-T cells engineered to not only attack infected cells but also persist long-term could offer a functional cure, controlling the virus in the absence of continuous drug therapy, a feat yet to be realized.

Central to this innovation is the design and implementation of a tri-cytokine fusion protein scaffold dubbed HCW9206, integrating IL-7, IL-15, and IL-21. These cytokines individually are integral to T cell homeostasis, survival, and memory formation, but their fusion into a single scaffold synergistically amplifies signals promoting the generation of durable CAR-T populations enriched in T memory stem cells (T_SCM). T_SCM cells represent a unique subset distinguished by their longevity, self-renewal capacity, and ability to differentiate into potent effector cells, thereby maintaining continuous immune protection.

The engineering process yields a CAR-T product with over 50% T_SCM phenotype cells, a stark contrast to the less than 5% achieved by conventional manufacturing. This shift profoundly impacts functional durability since T_SCM cells sustain prolonged antigen-specific responses, reconstituting the active cytotoxic pool over extended periods. The implications of this are pivotal for preventing relapse and managing chronic infections, where sustained immune pressure is critical.

Experimental murine models of human leukemia provided compelling validation. While both standard and scaffold-fabricated CAR-T cells initially eradicated cancerous cells effectively, only the multi-cytokine scaffold-modified cells re-expanded after subsequent tumor re-challenge, demonstrating a robust recall response that prevented disease resurgence. This property underscores the scaffold’s capacity to cultivate a cellular product capable of immunological memory akin to natural adaptive immunity.

Parallel investigations in a humanized mouse HIV model revealed that scaffold-engineered CAR-T cells manifested significantly greater antiviral activity, eradicating more HIV-infected cells compared to their standard counterparts. Notably, when applied to T cells derived from HIV-positive patients, the multi-cytokine scaffold methodology successfully eliminated infected cells, signaling readiness for translational adaptation.

Beyond therapeutic efficacy, this research suggests a refinement in CAR-T manufacturing protocols that could redefine the logistical and clinical paradigms of cell-based therapies. By incorporating cytokine signals that guide differentiation towards a stem memory phenotype at the point of ex vivo expansion, clinicians may enhance both the efficacy and sustainability of treatments, reducing relapse rates and potentially minimizing the need for repeated cell infusions.

Harris Goldstein, M.D., the study’s senior author and a leading figure in immunotherapy, emphasizes the transformative potential of this discovery. He envisions future CAR-T treatments not simply as transient tumor killers but as living drugs capable of self-renewal and persistent vigilance. This paradigm shift offers hope for cancer patients grappling with relapse and for millions living with HIV who currently require lifelong medication.

Further reinforcing the translational promise, the multi-cytokine scaffold’s design leverages subtle immunobiological principles. Each incorporated cytokine plays distinct but complementary roles: IL-7 fosters naive and memory T cell survival; IL-15 supports proliferative fitness and longevity; and IL-21 enhances functionality and memory phenotype maintenance. Together, by structurally uniting these cytokines, the scaffold creates a molecular milieu that biases the T cell culture towards a stem-like, self-maintaining state.

Notably, this approach addresses a critical manufacture bottleneck—current culture methods often drive T cells towards terminal differentiation or exhaustion, limiting their lifespan and efficacy. The cytokine fusion scaffold circumvents this by promoting a less differentiated, more therapeutically advantageous phenotype, a remarkable feat in cellular engineering that melds immunology with protein design.

The study was authored by a collaborative team spanning multiple institutions, including Einstein, Rockefeller University, HCW Biologics, Caring Cross, and the University of Texas Southwestern Medical Center. Funding was provided by the National Institutes of Health, underlining the significance of public investment in pioneering biomedical research.

Looking ahead, this cytokine fusion scaffold strategy may redefine standards across the burgeoning CAR-T field. The capacity to engineer CAR-T cells with intrinsic resilience and memory opens new horizons for tackling not only hematologic malignancies but infectious diseases characterized by persistent reservoirs or chronic infection. Moreover, it invites exploration of similar scaffold-based approaches to fine-tune cellular therapies targeting solid tumors and autoimmune disorders.

By revitalizing CAR-T cell longevity through molecular engineering of the ex vivo environment, the study heralds a future where living drugs maintain robust, durable antitumor and antiviral immunity. Such advancements push the envelope of personalized medicine, with the promise of delivering sustained remission, reduced relapse, and functional cures to patients worldwide.

Subject of Research: Animals

Article Title: IL-7/IL-15/IL-21 cytokine-fusion scaffold generates highly functional CAR-T cells enriched in long-lived T memory stem cells

News Publication Date: 13-Mar-2026

Image Credits: Albert Einstein College of Medicine

Keywords: Blood cancer, Leukemia, Cancer, Immune cells

Conventional T cell therapies, including CAR-T cells and T cell receptor (TCR) therapies, have shown remarkable clinical responses in certain blood cancers but face significant challenges when applied to solid tumors. A major hurdle involves the transient nature of infused T cells—they often lose efficacy as the immune cells either become exhausted or die off after a limited period. The UCLA team sought to address this challenge by reprogramming the patient’s hematopoietic stem cells to continuously generate fresh, cancer-specific T cells, potentially sustaining an anti-tumor immune response indefinitely. This strategy, in essence, implants a self-renewing immune system upgrade.

The clinical trial, published in Nature Communications, represents a first-in-human demonstration of this approach. Led by Dr. Theodore Scott Nowicki, alongside collaborators Dr. Antoni Ribas, Dr. Owen Witte, Dr. Donald Kohn, Dr. Lili Yang, and Dr. David Baltimore, the study leverages sophisticated gene therapy techniques to genetically modify stem cells with receptors that redirect T cells to recognize cancer-specific markers. Following genetic engineering, these modified stem cells are reintroduced into the patient via a bone marrow transplant, enabling long-term immune surveillance and attack against tumor cells.

One of the pivotal decisions in the trial involved targeting NY-ESO-1, a cancer-testis antigen that is selectively expressed in several tumor types, including melanoma and synovial sarcoma, while remaining largely absent in normal adult tissues. This selectivity reduces the risk of off-target effects and collateral damage to healthy cells, a critical consideration in the design of safe immunotherapies. Synovial sarcomas, in particular, exhibit high expression of NY-ESO-1, making this malignancy an ideal candidate for the pilot clinical trial.

The patient cohort consisted of individuals suffering from aggressive sarcomas, where conventional therapies often fall short and relapse rates are notoriously high. In these patients, even after chemotherapy or surgical resection, disease recurrence is common and treatment options remain limited. By focusing on this difficult-to-treat population, the study aimed to validate the feasibility and safety of implanting genetically modified stem cells as a durable cancer-fighting strategy.

Early outcomes from the trial were encouraging. Researchers observed successful engraftment of the engineered stem cells within the patients’ bone marrow, accompanied by the sustained production of cancer-specific T cells detectable for several months post-treatment. In one noteworthy case, tumor regression was documented, along with the persistence of newly generated immune cells that continuously surveilled and fought the malignancy. Imaging and molecular assays confirmed that the reprogrammed stem cells had taken root and were functioning as intended within the host.

Dr. Ribas emphasized that this pilot study substantiates the concept that the human immune system can be genetically programmed via stem cells to mount a renewable, cancer-directed response. This realization builds upon prior preclinical work from UCLA and Caltech laboratories, highlighting the translational potential of gene therapy techniques in regenerative immunology. Although these findings herald a major advance, the investigators caution that the approach remains experimental and complex, requiring sophisticated clinical management including stem cell collection, gene editing, conditioning chemotherapy, and careful post-transplant monitoring.

The procedure’s complexity and inherent risks underscore the necessity for specialized institutions and patient selection to maximize safety and efficacy. Nonetheless, parallels can be drawn to the early years of bone marrow transplantation, which initially presented logistical and clinical challenges but ultimately transformed patient care through technological refinement and experience accumulation. As such, the UCLA team anticipates that with further development, this therapy could become more accessible and streamlined.

Beyond oncology, the implications of using engineered stem cells as an enduring source of specialized immune cells extend to a broad spectrum of diseases. Dr. Nowicki suggests applications could include chronic viral infections like HIV, where long-lasting immune surveillance is critical, as well as autoimmune conditions, where immune modulation might be achieved by retraining the immune system. This modular, stem cell-based immune programming approach opens new avenues far beyond cancer, representing a transformative platform for immune engineering.

Perhaps the most profound takeaway from this research is the demonstration that it is biologically and clinically feasible to create a renewable, personalized immune defense against cancer by reprogramming the patient’s own stem cells. While not yet curative or widely available, this strategy challenges the paradigm of temporary treatments and stimulates vision for future immunotherapies that not only combat tumors but sustainably prevent their recurrence.

This milestone was achieved through a decade-long collaborative effort of over 30 scientists and clinicians, combining expertise in stem cell biology, gene therapy, oncology, and immunology. Acknowledging the extensive foundational work preceding the clinical trial, the investigators hope that this study catalyzes further research and accelerates the pathway toward next-generation immune cell therapies capable of delivering durable cancer control.

Funded by a consortium including the California Institute for Regenerative Medicine, the National Institutes of Health, Hyundai Hope on Wheels, the Tower Cancer Research Foundation, and the Parker Institute for Cancer Immunotherapy, this research exemplifies the power of integrated scientific innovation and cross-disciplinary collaboration. The involvement of faculty from UCLA’s David Geffen School of Medicine, the Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research, UCLA Health Jonsson Comprehensive Cancer Center, and the California Institute of Technology underpin the strength of this endeavor.

Looking ahead, the team is optimistic that continued refinement of genetic engineering methods, improved conditioning regimens, and enhanced understanding of tumor immunology will contribute to the broader application and increased safety of this stem cell-based immunotherapy platform. As progress accelerates, this novel paradigm has the potential to significantly shift clinical practice, enabling lifelong immune protection for cancer patients and redefining the ultimate goal of cancer treatment: not just remission, but durable cure and prevention.

Subject of Research: Cancer immunotherapy via genetically engineered hematopoietic stem cells producing tumor-specific T cells.
Article Title: Pioneering Stem Cell Engineering Yields Renewable Cancer-Fighting Immune Cells in Humans
News Publication Date: Not explicitly stated
Web References:

• Nature Communications article
• DOI link
  References: Clinical trial led by Dr. Theodore Scott Nowicki et al., published in Nature Communications in 2025.
  Image Credits: Not specified
  Keywords: Cancer, Sarcoma, Cancer research, Stem cells, Immunotherapy

The complexity of the tumor microenvironment remains one of the most daunting barriers to CAR-T efficacy. Within the TME, an intricate network of cellular and molecular components actively suppress immune effector functions, fostering tumor survival and growth. Immunosuppressive factors like regulatory T cells, myeloid-derived suppressor cells, and inhibitory cytokines conspire to limit the durability of CAR-T responses. This dynamic interplay not only blunts CAR-T cytotoxicity but also accelerates T cell exhaustion, characterized by diminished proliferative capacity and reduced cytokine secretion. Consequently, next-generation CAR-T cell designs are being meticulously engineered to resist these suppressive signals and maintain prolonged activity within hostile tumor niches.

Advances in genetic and molecular engineering have propelled the evolution of CAR constructs far beyond their original frameworks. New-generation CARs are equipped with diverse molecular modules that enhance recognition specificity, circumvent antigen escape, counteract inhibitory signals in the TME, and augment cytotoxic potency. Multi-target CAR-T cells, for instance, simultaneously recognize multiple tumor antigens, addressing the critical challenge of antigen heterogeneity and loss which often leads to tumor relapse. Furthermore, so-called TRUCKs—T cells Redirected for Universal Cytokine-mediated Killing—augment traditional CAR-T cytotoxicity by locally releasing cytokines that stimulate both the innate and adaptive arms of the immune response, effectively recruiting endogenous immune cells to aid in tumor clearance.

A particularly innovative approach involves the engineering of immune checkpoint-switching receptors that convert suppressive signals within the TME into activating cues for CAR-T cells. By rewiring inhibitory pathways into stimulatory ones, these receptors help sustain CAR-T function in an environment otherwise hostile to immune effectors. This dual role of checkpoint modulation not only enhances anti-tumor activity but also alleviates exhaustion, a state that markedly impairs long-term efficacy. The integration of these sophisticated signaling circuits underscores the increasing complexity and precision of CAR-T engineering strategies aimed at maximizing therapeutic outcomes.

Beyond modifications to receptor design, the field is exploring the integration of origins and sources of CAR-T cells to improve accessibility, safety, and persistence. Universal CAR-T platforms, including induced pluripotent stem cell (iPSC)-derived and in vivo-generated CAR-T cells, offer scalable alternatives to autologous products, which are limited by manufacturing complexities and variability. These universal platforms hold the promise of readily available “off-the-shelf” therapies with enhanced safety profiles and consistent functional characteristics. As researchers refine these models, the potential to revolutionize lymphoma treatment through broad accessibility is becoming increasingly tangible.

A burgeoning area of interest lies in the interplay between CAR-T cell metabolism, epigenetics, and functional longevity. Metabolic pathways such as glycolysis and oxidative phosphorylation meticulously govern CAR-T cell energy supply and differentiation status, influencing their proliferative capacity and exhaustion susceptibility. Epigenetic modifications, including histone acetylation and DNA methylation, further dictate CAR-T phenotypes by modulating gene expression programs pivotal to persistence and effector function. Understanding and manipulating these molecular processes promises a new frontier in CAR-T optimization, generating cells with enhanced durability and anti-tumor potency.

The intricate balance between efficacy and safety remains a central challenge as CAR-T designs grow increasingly sophisticated. While augmentations in cytotoxicity and immune stimulation heighten tumor eradication potential, they simultaneously pose increased risks of severe toxicities such as cytokine release syndrome and neurotoxicity. The field must navigate these trade-offs carefully, devising regulatory switches and safety mechanisms that enable powerful anti-tumor activity without compromising patient safety. This balancing act is complicated further by genetic risks introduced by complex engineering techniques, underscoring the need for meticulous preclinical validation and clinical monitoring.

In light of these complexities, the ideal CAR-T cell embodies multiple converging features: precise tumor antigen identification, robust and sustained cytotoxic activity, resistance to TME-induced exhaustion, high safety with minimized adverse events, flexible manufacturing, and broad accessibility. Achieving this multifaceted goal demands seamless integration of genetic engineering, immunology, and cellular metabolism insights. Ongoing research is steadily chipping away at long-held limitations, paving the way for CAR-T therapies that provide durable remissions and possibly cures for lymphoma patients worldwide.

The recent comprehensive review published by researchers at the Department of Hematology, the Second Affiliated Hospital of Zhejiang University School of Medicine encapsulates these advances and emerging strategies. This work systematically dissects the molecular mechanisms underpinning various CAR-T modification approaches designed to counteract tumor immune evasion and repressive microenvironments. By detailing novel CAR architectures and their functional benefits, the review contextualizes how each innovation contributes to overcoming specific therapeutic bottlenecks. Their findings extend beyond current clinical CAR-T products, highlighting promising preclinical and translational developments poised to redefine lymphoma immunotherapy.

Notably, the review explores how epigenetic and metabolic controls modulate CAR-T cell fate and efficacy, offering valuable perspectives for future research directions. These convergent networks are tightly regulated, influencing exhaustion and immune memory, thereby shaping systemic antitumor immunity. By appreciating this complexity, researchers can design holistic strategies that not only enhance the intrinsic activity of CAR-T cells but also prolong their functional lifespan within patients, a key factor for sustained clinical benefit.

While the promise of next-generation CAR-T therapies is undeniable, the path forward is fraught with scientific and technical challenges. The progressive layering of modifications increases manufacturing complexity and potential off-target risks. Moreover, conflicts may arise between strategies designed to enhance memory versus those that prioritize immediate cytotoxicity, or between mechanisms promoting lethality and those safeguarding safety. Navigating these intricacies requires judicious design choices and balanced clinical evaluation to develop optimized CAR-T therapies that fulfill the promise of personalized, effective lymphoma treatment.

In summary, the field of lymphoma CAR-T therapy is accelerating rapidly, fueled by cross-disciplinary innovations in synthetic biology, immunology, and genomics. The future of CAR-T treatment lies in the development of multifunctional, robust cellular therapeutics capable of surmounting the myriad obstacles posed by tumors and their environments. With continued collaborative effort, it is plausible that these advanced CAR-T cells will bring about a paradigm shift in oncology, offering lymphoma patients more durable remissions, improved quality of life, and hope for long-term cure.

Subject of Research: Immunotherapeutic enhancements in CAR-T cell therapy for lymphoma

Article Title: Advances in strategies to improve the immunotherapeutic efficacy of chimeric antigen receptor-T cell therapy for lymphoma

News Publication Date: 15-Apr-2025

Web References: DOI: 10.20892/j.issn.2095-3941.2024.0538

References: Information sourced from the published review from the Department of Hematology, the Second Affiliated Hospital, Zhejiang University School of Medicine, Cancer Biology & Medicine, 2025